Top

BioDrugs

Published in:

01-01-2003 | Therapy Review

Recombinant Human Thyroid-Stimulating Hormone

Pharmacology, Clinical Applications and Potential Uses

Authors: Professor Charles H. Emerson, Mira S. T. Torres

Published in: BioDrugs | Issue 1/2003

Abstract

The major functions of pituitary thyroid-stimulating hormone (TSH) are to maintain the biosynthesis and secretion of the thyroid hormones L-thyroxine (T4) and L-3,5,3′triidothyronine (T3). The TSH core contains two apoproteins, the α and β subunits. The α subunit is identical to that of pituitary follitropin, pituitary lutropin and placental chorionic gonadotropin, whereas the β subunit is unique. TSH is a glycoprotein; the glycoprotein components of the a and β subunits account for more than 10% of their mass and are essential for normal thyrotropic action and intravascular kinetics. The hypothalamic tripeptide, TSH-releasing hormone (TRH) is required for optimum TSH biosynthesis, particularly as far as addition of the glycoprotein components is concerned. TRH deficiency is associated with secretion of TSH molecules that are appropriately measured in most assays but have reduced bioactivity. In previous years the TSH used in clinical practice was obtained and purified from bovine pituitaries. Bovine TSH was used to test thyroid function and to augment the uptake of radioiodine in patients with thyroid cancer. Bovine TSH has been largely abandoned as a clinical agent because of adverse immune reactions.

A recombinant human TSH (rhTSH; Thyrogen®¹), has been approved by the US FDA for diagnostic use in patients with thyroid cancer. The a and β subunits of Thyrogen® are identical to those of human pituitary TSH. Thyrogen® has a specific activity of approximately 4 IU/mg and is a potent stimulator of T4, T3 and thyroglobulin (Tg) secretion in healthy volunteers. It also increases thyroid iodide uptake in patients with thyroid cancer or multinodular goitre and in volunteers, even those exposed to large amounts of stable iodide. Thyroid cancer patients who have been treated by thyroidectomy and radioiodine ablation but are at risk of harbouring residual thyroid cancer are candidates for Thyrogen® administration to prepare them for whole body iodide scans and serum Tg measurements. In thyroidectomised thyroid cancer patients who are unable to secrete pituitary TSH upon thyroid hormone withdrawal, Thyrogen® is the only acceptable method to prepare them for these procedures. Thyrogen® has been used on a compassionate basis to prepare patients for radioiodine ablation. rhTSH, in addition to being useful in the management of patients with thyroid cancer, is potentially useful to test thyroid reserve and to aid in thyroid-related nuclear medicine procedures. In the future, TSH analogues that have superagonist or antagonist properties may become available as therapeutic agents.

Will RG. An overview of Creutzfeldt-Jakob disease associated with the use of human pituitary growth hormone. Dev Biol Stand 1991; 75: 85–6PubMed

Bannister BA, McCormick A. Creutzfeldt-Jakob disease with reference to the safety of pituitary growth hormone. J Infect 1987; 14: 7–12PubMed

Kirkpatrick CH, Meek JC, Rich RR. Mechanism of allergy to components of commercial bovine thyrotropin. J Allergy Clin Immunol 1973; 51: 296–302PubMed

Krishnamurthy GT. Human reaction to bovine TSH: concise communication. J Nucl Med 1978; 19: 284–6PubMed

Sain A, Sham R, Singh A, et al. Erroneous thyroid-stimulating hormone radioimmunoassay results due to interfering antibovine thyroid-stimulating hormone antibodies. Am J Clin Pathol 1979; 71: 540–2PubMed

Sherman WB, Werner SC. Generalized allergic reaction to bovine thyrotropin. JAMA 1964; 190: 244–5PubMed

Weintraub BD, Szkudlinski MW. Development and in vitro characterization of human recombinant thyrotropin. Thyroid 1999; 9: 447–50PubMed

Meier C, Braverman L, Ebner S, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994; 78: 188–96PubMed

Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma [see comments]. N Engl J Med 1997; 337: 888–96PubMed

10.

Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877–85PubMed

11.

Park ES, Kim H, Suh JM, et al. Involvement of JAK/STAT (Janus kinase/signal transducer and activator of transcription) in the thyrotropin signaling pathway. Mol Endocrinol 2000; 14: 662–70PubMed

12.

Robbins J. Pharmacology of bovine and human thyrotropin: an historical perspective. Thyroid 1999; 9: 451–3PubMed

13.

Magner JA. Thyroid-stimulating hormone: biosynthesis, cell biology, and bioactivity. Endocr Rev 1990; 11: 354–85PubMed

14.

Di Cerbo A, Corda D. Signaling pathways involved in thyroid hyperfunction and growth in Graves’ disease. Biochimie 1999; 81: 415–24PubMed

15.

Roger PP, Christophe D, Dumont JE, et al. The dog thyroid primary culture system: a model of the regulation of function, growth and differentiation expression by cAMP and other well-defined signaling cascades. Eur J Endocrinol 1997; 137: 579–98PubMed

16.

Gesundheit N, Petrick PA, Nissim M, et al. Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Case reports and follow-up of nine patients. Ann Intern Med 1989; 111: 827–35PubMed

17.

Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. EndocrRev 1992; 13: 596–611

18.

Rapoport B, Chazenbalk GD, Jaume JC, et al. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 1998; 19: 673–716PubMed

19.

Sanders J, Oda Y, Roberts SA, et al. Understanding the thyrotropin receptor function-structure relationship. Baillieres Clin Endocrinol Metab 1997; 11: 451–79PubMed

20.

Misrahi M, Loosfelt H, Atger M, et al. Cloning, sequencing and expression of human TSH receptor. Biochem Biophys Res Commun 1990; 166: 394–403PubMed

21.

Loosfelt H, Pichon C, Jolivet A, et al. Two-subunit structure of the human thyrotropin receptor. Proc Natl Acad sci U S A 1992; 89: 3765–9PubMed

22.

Hara T, Namba H, Takamura N, et al. Thyrotropin regulates c-Jun N-terminal kinase (JNK) activity through two distinct signal pathways in human thyroid cells. Endocrinology 1999; 140: 1724–30PubMed

23.

Dumont JE. The action of thyrotropin on thyroid metabolism. Vitam Horm 1971; 29: 287–412PubMed

24.

Laurent E, Mockel J, Van Sande J, et al. Dual activation by thyrotropin of the phospholipase C and cyclic AMP cascades in human thyroid. Mol Cell Endocrinol 1987; 52: 273–8PubMed

25.

Raspe E, Laurent E, Andry G, et al. ATP, bradykinin, TRH and TSH activate the Ca(2+)-phosphatidylinositol cascade of human thyrocytes in primary culture. Mol Cell Endocrinol 1991; 81: 175–83PubMed

26.

Corvilain B, Laurent E, Lecomte M, et al. Role of the cyclic adenosine 3′, 5′-mono-phosphate and the phosphatidylinositol-Ca2+ cascades in mediating the effects of thyrotropin and iodide on hormone synthesis and secretion in human thyroid slices. J Clin Endocrinol Metab 1994; 79: 152–9PubMed

27.

Spitzweg C, Heufelder AE, Morris JC. Thyroid iodine transport. Thyroid 2000 Apr; 10: 321–30PubMed

28.

Yoshidi A, Taniguchi S, Hisatome I, et al. Pendrin is an iodide-specific apical porter responsible for iodide efflux from thyroid cells. J Clin Endocrinol Metab 2002; 87: 3356–61

29.

Ohtaki S, Nakagawa H, Nakamura M, et al. Thyroid peroxidase: experimental and clinical integration. Endocr J 1996; 43: 1–14PubMed

30.

Taurog A. Molecular evolution of thyroid peroxidase. Biochimie 1999; 81: 557–62PubMed

31.

Dunn JT, Dunn AD. The importance of thyroglobulin structure for thyroid hormone biosynthesis. Biochimie 1999; 81: 505–9PubMed

32.

Baudry N, Lejeune PJ, Niccoli P, et al. Dityrosine bridge formation and thyroid hormone synthesis are tightly linked and are both dependent on N-glycans. FEBS Lett 1996; 396: 223–6PubMed

33.

Bernier-Valentin F, Kostrouch Z, Rabilloud R, et al. Coated vesicles from thyroid cells carry iodinated thyroglobulin molecules. First indication for an internalization of the thyroid prohormone via a mechanism of receptor-mediated endocytosis. J Biol Chem 1990; 265: 17373–80PubMed

34.

Kostrouch Z, Munari-Silem Y, Rajas F, et al. Thyroglobulin internalized by thyrocytes passes through early and late endosomes. Endocrinology 1991; 129: 2202–11PubMed

35.

Bernier-Valentin F, Kostrouch Z, Rabilloud R, et al. Analysis of the thyroglobulin internalization process using in vitro reconstituted thyroid follicles: evidence for a coated vesicle-dependent endocytic pathway. Endocrinology 1991; 129: 2194–201PubMed

36.

Dunn AD, Crutchfield HE, Dunn JT. Proteolytic processing of thyroglobulin by extracts of thyroid lysosomes. Endocrinology 1991; 128: 3073–80PubMed

37.

Rousset B, Selmi S, Alquier C, et al. In vitro studies of the thyroglobulin degradation pathway: endocytosis and delivery of thyroglobulin to lysosomes, release of thyroglobulin cleavage products —iodotyrosines and iodothyronines. Biochimie 1989; 71: 247–62PubMed

38.

Rousset B, Selmi S, Bornet H, et al. Thyroid hormone residues are released from thyroglobulin with only limited alteration of the thyroglobulin structure. J Biol Chem 1989; 264: 12620–6PubMed

39.

Uller RP, Van Herle AJ, Chopra IJ. Comparison of alterations in circulating thyroglobulin, triiodothyronine and thyroxine in response to exogenous (bovine) and endogenous (human) thyrotropin. J Clin Endocrinol Metab 1973; 37: 741–5PubMed

40.

Uller R, van Herle A, Chopra I. Thyroidal response to graded doses of bovine thyrotropin. J Clin Endocrinol Metab 1977; 45: 312–8PubMed

41.

Unger J, van Heuverswyn B, Decoster C, et al. Thyroglobulin and thyroid hormone release after intravenous administration of bovine thyrotropin in man. J Clin Endocrinol Metab 1980; 51: 590–4PubMed

42.

Ramirez L, Braverman L, White B, et al. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J Clin Endocrinol Metab 1997; 82: 2836–9PubMed

43.

Torres MS, Ramirez L, Simkin PH, et al. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 2001; 86: 1660–4PubMed

44.

Colletta G, Cirafici AM. TSH is able to induce cell cycle-related gene expression in rat thyroid cell. Biochem Biophys Res Commun 1992; 183: 265–72PubMed

45.

Filetti S, Damante G, Foti D. Thyrotropin stimulates glucose transport in cultured rat thyroid cells. Endocrinology 1987; 120: 2576–81PubMed

46.

Haraguchi K, Rani CS, Field JB. Effects of thyrotropin, carbachol, and protein kinase-C stimulators on glucose transport and glucose oxidation by primary cultures of dog thyroid cells. Endocrinology 1988; 123: 1288–95PubMed

47.

Grossmann M, Weintraub BD, Szkudlinski MW. Novel insights into the molecular mechanisms of human thyrotropin action: structural, physiological, and therapeutic implications for the glycoprotein hormone family. Endocr Rev 1997; 18: 476–501PubMed

48.

Fiddes JC, Goodman HM. The gene encoding the common alpha subunit of the four human glycoprotein hormones. J Mol Appl Genet 1981; 1: 3–18PubMed

49.

Lustbader JW, Lobel L, Wu H, et al. Structural and molecular studies of human chorionic gonadotropin and its receptor. Recent Prog Horm Res 1998; 53: 395–424PubMed

50.

Pigny P, Berault A, Dewailly D, et al. Glycoprotein hormones, glycosylation and biological activity. Ann Biol Clin (Paris) 1992; 50: 557–64

51.

Taylor T, Weintraub BD. Altered thyrotropin (TSH) carbohydrate structures in hypothalamic hypothyroidism created by paraventricular nuclear lesions are corrected by in vivo TSH-releasing hormone administration. Endocrinology 1989; 125: 2198–203PubMed

52.

Taylor T, Gesundheit N, Gyves PW, et al. Hypothalamic hypothyroidism caused by lesions in rat paraventricular nuclei alters the carbohydrate structure of secreted thyrotropin. Endocrinology 1988; 122: 283–90PubMed

53.

Beck-Peccoz P, Persani L. Variable biological activity of thyroid-stimulating hormone. Eur J Endocrinol 1994; 131: 331–40PubMed

54.

Persani L. Hypothalamic thyrotropin-releasing hormone and thyrotropin biological activity. Thyroid 1998; 8: 941–6PubMed

55.

Weintraub BD, Wondisford FE, Farr A, et al. Pre-translational and post-trans-lational regulation of TSH: relationship to bioactivity. Horm Metab Res Suppl 1990; 23: 9–11PubMed

56.

Schaaf L, Leiprecht A, Saji M, et al. Glycosylation variants of human TSH selectively activate signal transduction pathways. Mol Cell Endocrinol 1997; 132: 185–94PubMed

57.

Thotakura NR, Desai RK, Bates LG, et al. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 1991; 128: 341–8PubMed

58.

Szkudlinski MW, Thotakura NR, Bucci I, et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology 1993; 133: 1490–503PubMed

59.

Grossmann M, Szkudlinski MW, Tropea JE, et al. Expression of human thyrotropin in cell lines with different glycosylation patterns combined with mutagenesis of specific glycosylation sites. Characterization of a novel role for the oligosaccharides in the in vitro and in vivo bioactivity. J Biol Chem 1995; 270: 29378–85PubMed

60.

Szkudlinski MW, Thotakura NR, Weintraub BD. Subunit-specific functions of N-linked oligosaccharides in human thyrotropin: role of terminal residues of alpha- and beta-subunit oligosaccharides in metabolic clearance and bioactivity. Proc Natl Acad sci U S A 1995; 92: 9062–6PubMed

61.

Grossmann M, Wong R, Teh NG, et al. Expression of biologically active human thyrotropin (hTSH) in a baculovirus system: effect of insect cell glycosylation on hTSH activity in vitro and in vivo. Endocrinology 1997; 138: 92–100PubMed

62.

Szkudlinski MW, Grossmann M, Leitolf H, et al. Human thyroid-stimulating hormone: structure-function analysis. Methods 2000 May; 21: 67–81PubMed

63.

Persani L, Terzolo M, Asteria C, et al. Circadian variations of thyrotropin bioactivity in normal subjects and patients with primary hypothyroidism. J Clin Endocrinol Metab 1995; 80: 2722–8PubMed

64.

Papandreou MJ, Persani L, Asteria C, et al. Variable carbohydrate structures of circulating thyrotropin as studied by lectin affinity chromatography in different clinical conditions. J Clin Endocrinol Metab 1993; 77: 393–8PubMed

65.

Dahlberg PA, Petrick PA, Nissim M, et al. Intrinsic bioactivity of thyrotropin in human serum is inversely correlated with thyroid hormone concentrations. Application of a new bioassay using the FRTL-5 rat thyroid cell strain. J Clin Invest 1987; 79: 1388–94PubMed

66.

Nissim M, Lee KO, Petrick PA, et al. A sensitive thyrotropin (TSH) bioassay based on iodide uptake in rat FRTL-5 thyroid cells: comparison with the adenosine 3′,5′-monophosphate response to human serum TSH and enzymatically deglycosylated bovine and human TSH. Endocrinology 1987; 121: 1278–87PubMed

67.

Persani L, Tonacchera M, Beck-Peccoz P, et al. Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin. J Endocrinol Invest 1993; 16: 511–9PubMed

68.

Beck-Peccoz P, Amr S, Menezes-Ferreira MM, et al. Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. N Engl J Med 1985; 312: 1085–90PubMed

69.

Horimoto M, Nishikawa M, Yoshikawa N, et al. A sensitive and practical bioassay for thyrotropin (TSH): comparison of the bioactivity of TSH in normal subjects and in patients with primary hypothyroidism. Endocrinol Jpn 1990; 37: 577–81PubMed

70.

Persani L, Asteria C, Tonacchera M, et al. Evidence for the secretion of thyrotropin with enhanced bioactivity in syndromes of thyroid hormone resistance. J Clin Endocrinol Metab 1994; 78: 1034–9PubMed

71.

Beck-Peccoz P, Piscitelli G, Amr S, et al. Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and alpha-subunit: evidence for secretion of TSH with increased bioactivity. J Clin Endocrinol Metab 1986; 62: 704–11PubMed

72.

Shupnik MA, Greenspan SL, Ridgway EC. Transcriptional regulation of thyrotropin subunit genes by thyrotropin-releasing hormone and dopamine in pituitary cell culture. J Biol Chem 1986; 261: 12675–9PubMed

73.

Gesundheit N, Magner JA, Chen T, et al. Differential sulfation and sialylation of secreted mouse thyrotropin (TSH) subunits: regulation by TSH-releasing hormone. Endocrinology 1986; 119: 455–63PubMed

74.

Gesundheit N, Fink DL, Silverman LA, et al. Effect of thyrotropin-releasing hormone on the carbohydrate structure of secreted mouse thyrotropin. Analysis by lectin affinity chromatography. J Biol Chem 1987; 262: 5197–203PubMed

75.

Ronin C, Stannard BS, Weintraub BD. Differential processing and regulation of thyroid-stimulating hormone subunit carbohydrate chains in thyrotropic tumors and in normal and hypothyroid pituitaries. Biochemistry 1985; 24: 5626–31PubMed

76.

Menezes-Ferreira MM, Petrick PA, Weintraub BD. Regulation of thyrotropin (TSH) bioactivity by TSH-releasing hormone and thyroid hormone. Endocrinology 1986; 118: 2125–30PubMed

77.

Yamada M, Saga Y, Shibusawa N, et al. Tertiary hypothyroidism and hyperglycemia in mice with targeted disruption of the thyrotropin-releasing hormone gene. Proc Natl Acad sci U S A 1997; 94: 10862–7PubMed

78.

Abel ED, Kaulbach HC, Campos-Barros A, et al. Novel insight from transgenic mice into thyroid hormone resistance and the regulation of thyrotropin. J Clin Invest 1999; 103: 271–9PubMed

79.

Snyder PJ, Utiger RD. Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormones. J Clin Invest 1972; 51: 2077–84PubMed

80.

Segerson TP, Kauer J, Wolfe HC, et al. Thyroid hormone regulates TRH biosynthesis in the paraventricular nucleus of the rat hypothalamus. Science 1987; 238: 78–80PubMed

81.

Koller KJ, Wolff RS, Warden MK, et al. Thyroid hormones regulate levels of thyrotropin-releasing-hormone mRNA in the paraventricular nucleus. Proc Natl Acad sci U S A 1987; 84: 7329–33PubMed

82.

Kakucska I, Rand W, Lechan RM. Thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus is dependent upon feedback regulation by both triiodothyronine and thyroxine. Endocrinology 1992; 130: 2845–50PubMed

83.

Faglia G, Bitensky L, Pinchera A, et al. Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biological activity of immunoreactive thyrotropin. J Clin Endocrinol Metab 1979; 48: 989–98PubMed

84.

Emerson CH. Central hypothyroidism and hyperthyroidism. Med Clin North Am 1985; 69: 1019–34PubMed

85.

Miura Y, Perkel VS, Papenberg KA, et al. Concanavalin-A, lentil, and ricin lectin affinity binding characteristics of human thyrotropin: differences in the sialylation of thyrotropin in sera of euthyroid, primary, and central hypothyroid patients. J Clin Endocrinol Metab 1989; 69: 985–95PubMed

86.

DeCherney GS, Gesundheit N, Gyves PW, et al. Alterations in the sialylation and sulfation of secreted mouse thyrotropin in primary hypothyroidism. Biochem Biophys Res Commun 1989; 159: 755–62PubMed

87.

Schaaf L, Trojan J, Helton TE, et al. Serum thyrotropin (TSH) heterogeneity in euthyroid subjects and patients with subclinical hypothyroidism: the core fucose content of TSH-releasing hormone-released TSH is altered, but not the net charge of TSH. J Endocrinol 1995; 144: 561–71PubMed

88.

Wondisford FE, Radovick S, Moates JM, et al. Isolation and characterization of the human thyrotropin beta-subunit gene. Differences in gene structure and promoter function from murine species. J Biol Chem 1988; 263: 12538–42PubMed

89.

Watanabe S, Hayashizaki Y, Endo Y, et al. Production of human thyroid-stimulating hormone in Chinese hamster ovary cells. Biochem Biophys Res Commun 1987; 149: 1149–55PubMed

90.

Cole ES, Lee K, Lauziere K, et al. Recombinant human thyroid stimulating hor-mone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology 1993; 11: 1014–24PubMed

91.

Hussain A, Zimmerman CA, Boose JA, et al. Large scale synthesis of recombinant human thyrotropin using methotrexate amplification: Chromatographie, im-munological, and biological characterization. J Clin Endocrinol Metab 1996; 81: 1184–8PubMed

92.

Rafferty B, Gaines Das R. Comparison of pituitary and recombinant human thy-roid-stimulating hormone (rhTSH) in a multicenter collaborative study: estab-lishment of the first World Health Organization reference reagent for rhTSH. Clin Chem 1999; 45: 2207–15PubMed

93.

Szkudlinski MW, Thotakura NR, Tropea JE, et al. Asparagine-linked oligosac-charide structures determine clearance and organ distribution of pituitary and recombinant thyrotropin. Endocrinology 1995; 136: 3325–30PubMed

94.

Huber GK, Fong P, Concepcion ES, et al. Recombinant human thyroid-stimulat-ing hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab 1991; 72: 1328–31PubMed

95.

Braverman L, Pratt B, Ebner S, et al. Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the rhesus monkey. J Clin Endocrinol Metab 1992; 74: 1135–9PubMed

96.

Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 2000; 85: 3592–6PubMed

97.

East-Palmer J, Szkudlinski MW, Lee J, et al. A novel, nonradioactive in vivo bioassay of thyrotropin (TSH). Thyroid 1995; 5: 55–9PubMed

98.

Colzani RM, Alex S, Fang SL, et al. The effect of recombinant human thyrotropin (rhTSH) on thyroid function in mice and rats. Thyroid 1998; 8: 797–801PubMed

99.

Thyrogen. In: Physicians Desk Reference, 56th ed. Montvale (NJ): Medical Eco-nomics Co. Inc., 2002: 1441-2

100.

Ridgway EC, Weintraub BD, Maloof F. Metabolic clearance and production rates of human thyrotropin. J Clin Invest 1974; 53: 895–903PubMed

101.

Kuku SF, Harsoulis P, Kjeld M, et al. Human thyrotrophic hormone kinetics and effects in euthyroid males. Horm Metab Res 1975; 7: 54–9

102.

Dulgeroff AJ, Hershman JM. Medical therapy for differentiated thyroid carci-noma. EndocrRev 1994; 15: 500–15

103.

Mazzaferri EL. An overview of the management of papillary and f ollicular thyroid carcinoma. Thyroid 1999; 9: 421–7PubMed

104.

Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002; 87: 3242–7PubMed

105.

Emerson CH, Colzani R, Braverman LE. Epithelial cell thyroid cancer and thyroid stimulating hormone -when less is more. J Clin Endocrinol Metab 1997; 82: 9–10PubMed

106.

Durski JM, Weigel RJ, McDougall IR. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Nucl Med Commun 2000; 21: 521–8PubMed

107.

Hershman JM. Recombinant human thyrotropin. Thyroid 1999; 9: 419–20PubMed

108.

Incerti C. Recombinant human thyroid-stimulating hormone (rhTSH): clinical development. J Endocrinol Invest 1999; 22: 8–16PubMed

109.

Ladenson PW. Strategies for thyrotropin use to monitor patients with treated thy-roid carcinoma. Thyroid 1999; 9: 429–33PubMed

110.

Ladenson PW. Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 2000; 30: 98–106PubMed

111.

Mariani G, Ferdeghini M, Augeri C, et al. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differenti-ated thyroid cancer. Cancer Biother Radiopharm 2000; 15: 211–7PubMed

112.

Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 2000 Sep; 10: 767–78PubMed

113.

McDougall IR, Weigel RJ. Recombinant human thyrotropin in the management of thyroid cancer. Curr Opin Oncol 2001; 13: 39–43PubMed

114.

Pacini F, Lippi F. Clinical experience with recombinant human thyroid-stimulat-ing hormone (rhTSH): serum thyroglobulin measurement. J Endocrinol Invest 1999; 22: 25–9PubMed

115.

Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. J Endocrinol Invest 1999; 22: 30–4PubMed

116.

Reiners C, Luster M, Lassmann M. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131. J Endocrinol Invest 1999; 22: 17–24PubMed

117.

Robbins RJ, Tuttle RM, Sharaf RN, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 619–25PubMed

118.

Robbins R, Drucker W, Hann L, et al. Advances in the detection of residual thyroid carcinoma. Adv Intern Med 2001; 46: 277–94PubMed

119.

Schlumberger MJ, Incerti C, Pacini F, et al. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion. J Endocrinol Invest 1999; 22: 35–41PubMed

120.

Schlumberger M, Ricard M, Pacini F. Clinical use of recombinant human TSH in thyroid cancer patients. Eur J Endocrinol 2000; 143: 557–63PubMed

121.

Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thy-roid ablation? J Clin Endocrinol Metab; 87: 1490-8

122.

Haugen BR, Ridgway EC, McLaughlin BA, et al. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recom-binant human thyrotropin. Thyroid 2002; 12: 37–43PubMed

123.

Giovanni V, Arianna LG, Antonio C, et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol 2002; 56: 247–52

124.

Berg G, Lindstedt G, Suurkula M, et al. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002; 25: 44–52PubMed

125.

Wartofsky L. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 2002 Jul; 12(7): 583–90PubMed

126.

Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up or differenti-ated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 5686–90PubMed

127.

Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical ther-apy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418–28PubMed

128.

Petrich T, Borner AR, Otto D, et al. Influence of rhTSH on [(18)F]fluro-deoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med 2002; 29: 641–7

129.

Vargas GE, Uy H, Bazan C, et al. Hemiplegia after thyrotropin alfa in a hypothy-roid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 1999; 84: 3867–71PubMed

130.

Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001; 86: 5148–51PubMed

131.

Robbins RJ, Voelker E, Wang W, et al. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of the literature. Endocr Pract 2000; 6: 460–4PubMed

132.

Lippi F, Capezzone M, Angelini F, et al. Radioiodine treatment of metastatic differentiated thyroid cancer on L-thyroxine using recombinant TSH. Eur J Endocrinol 2001; 144: 5–11PubMed

133.

Luster M, Lassmann M, Haenscheid H, et al. Use of recombinant human thyro-tropin before radioiodine therapy in patients with advanced differentiated thy-roid carcinoma. J Clin Endocrinol Metab 2000; 85: 3640–5PubMed

134.

Seidlin SM, Oshry E, Yallow AA. Spontaneous and experimentally induced up-take of radioactive iodine in métastases from thyroid carcinoma: a preliminary report. J Clin Endocrinol 1948; 8: 423–32

135.

Trannell JB, Marinelli LD, Duffy BJ, et al. The treatment of metastatic thyroid cancer with radioactive iodine: a preliminary report. J Clin Endocrinol 1949; 9: 1138–52

136.

Benua RS, Sonenberg M, Leeper RD, et al. An 18 year study of the use of beef thyrotropin to increase 1131 uptake in metastatic thyroid cancer. J Nucl Med 1964; 5: 796–801

137.

Hershman J, Edwards C. Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: implications for 131-1 treatment of thyroid carcinoma. J Clin Endocrinol Metab 1972; 34: 814–8PubMed

138.

Ringel M, Ladenson P. Diagnostic accuracy of 1311 scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab 1996; 81: 1724–5PubMed

139.

Masiukiewicz US, Nakchbandi IA, Stewart AF, et al. Papillary thyroid carcinoma metastatic to the pituitary gland. Thyroid 1999; 9: 1023–7PubMed

140.

Colleran KM, Burge MR. Isolated thyrotropin deficiency secondary to primary empty sella in a patient with differentiated thyroid carcinoma: an indication for recombinant thyrotropin. Thyroid 1999; 9: 1249–52PubMed

141.

Luster M, Reinhardt W, Korber C, et al. The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production. J Endocrinol Invest 2000; 23: 473–5PubMed

142.

Rotman-Pikielny P, Reynolds JC, Barker WC, et al. Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. J Clin Endocrinol Metab 2000; 85: 237–44PubMed

143.

Bray GA, Melvin KE, Chopra IJ. Effect of triiodothyronine on some metabolic responses of obese patients. Am J Clin Nutr 1973; 26: 715–21PubMed

144.

Potter JD. Hypothyroidism and reproductive failure. Surg Gynecol Obstet 1980; 150: 251–5PubMed

145.

Bishopric GA, Garrett NH, Nicholson WM. Clinical value of the TSH test in the diagnosis of thyroid diseases. Am J Med 1955; 18: 15–9PubMed

146.

Skillern PG, Evans BR. The thyroid stimulating hormone (TSH) test. An aid to the differential diagnosis of nontoxic disease of the thyroid. Arch Intern Med 1957; 99: 266–77

147.

Rosen HN, Greenspan SL, Landsberg L, et al. Distinguishing hypothyroxinemia due to euthyroid sick syndrome from pituitary insufficiency. Isr J Med sci 1994; 30: 746–50PubMed

148.

Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43: 55–68

149.

Burke G. The thyrotropin stimulation test. Ann Intern Med 1968; 69: 1127–39PubMed

150.

Stanley MM, Astwood EB. The response of the thyroid gland in normal human subjects to the administration of thyrotropin, as shown by studies with 1131. Endocrinology 1949; 44: 49–60PubMed

151.

Querido A, Stanbury JB. The response of the thyroid gland to thyrotropic hormone as an aid in the differential diagnosis of primary and secondary hypothyroidism. J Clin Endocrinol Metab 1950; 10: 1192–201PubMed

152.

Perloff WH, Levy LM, Despopoulos A. The use of thyrotropic hormone (TSH) in the diagnosis of myxedema. J Clin Endocrinol 1952; 11: 1495–502

153.

Einhorn J, Larsson LG. Studies on the effect of thyrotropin on human thyroid function. J Clin Endocrinol 1959; 19: 28–34

154.

Taunton O, McDaniel H, Pittman J. Standardization of TSH testing. Ann Intern Med 1965; 25: 266–77

155.

Nelson J, Johnson D, Odell W. Serum TSH levels and the thyroidal response to TSH stimulation in patients with thyroid disease. Ann Intern Med 1972; 76: 47–52PubMed

156.

Wiener R, Utiger RD, Lew R, et al. Age, sex, and serum thyrotropin concentrations in primary hypothyroidism. Acta Endocrinol (Copenh) 1991; 124: 364–9

157.

Refetoff S, Sunthornthepvarakul T, Gottschalk ME, et al. Resistance to thyrotropin and other abnormalities of the thyrotropin receptor. Recent Prog HormRes 1996; 51: 97–120

158.

Fares FA, Levi F, Reznick AZ, et al. Engineering a potential antagonist of human thyrotropin and thyroid stimulating antibody. J Biol Chem2001; 2000; 16: 4543–8

159.

Sathekge MM, Mageza RB, Muthuphei MN, et al. Evaluation of thyroid nodules with technetium-99m MIBI and technetium-99m pertechnetate. Head Neck 2001 Apr; 23: 305–10PubMed

160.

Braverman LE. Iodine and the thyroid: 33 years of study. Thyroid 1994; 4: 351–6PubMed

161.

Knopp J, Stolc V, Tong W. Evidence for the induction of iodide transport in bovine thyroid cells treated with thyroid-stimulating hormone or dibutyryl cyclic adenosine 3′,5′-monophosphate. J Biol Chem 1970; 245: 4403–8PubMed

162.

Lawrence JE, Emerson CH, Sullaway SL, et al. The effect of recombinant human TSH on the thyroid (123)I uptake in iodide treated normal subjects. J Clin Endocrinol Metab 2001; 86: 437–40PubMed

163.

Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, et al. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 2001; 86: 5330–6PubMed

Title: Recombinant Human Thyroid-Stimulating Hormone
Pharmacology, Clinical Applications and Potential Uses
Authors: Professor Charles H. Emerson
Mira S. T. Torres
Publication date: 01-01-2003
Publisher: Springer International Publishing
Published in: BioDrugs / Issue 1/2003
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.2165/00063030-200317010-00003

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Recombinant Human Thyroid-Stimulating Hormone

Pharmacology, Clinical Applications and Potential Uses

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2003

Amotosalen

Pramlintide

Interleukin-12

Profile Summary

Recent Advances in the Development of an Inhaled Insulin Product

Prevention Strategies for Type 1 Diabetes Mellitus